CAR T-cell Therapy Approved for Certain Blood Cancers
Lisocabtagene maraleucel was approved for some patients with advanced CLL or SLL. The U.S. Food and Drug Administration (FDA)...
Lisocabtagene maraleucel was approved for some patients with advanced CLL or SLL. The U.S. Food and Drug Administration (FDA)...
The BCR-ABL inhibitor ponatinib was approved for some patients with acute lymphoblastic leukemia. The U.S. Food and Drug Administration...
Cancer immunotherapy is making headlines and generating excitement among biomedical researchers, clinicians, patients and their families, and research advocates....
The FDA has approved osimertinib plus chemotherapy for non-small cell lung cancer with EGFR mutations. The U.S. Food and...
The FDA has approved amivantamab-vmjw, both alone and in combination with chemotherapy, for the treatment of certain non-small cell...
The former president, who announced in August 2015 he had metastatic melanoma, recently said he was cancer-free after treatment...
The FDA approved the use of an immunotherapeutic in combination with chemotherapy to treat certain patients with triple-negative breast...
The U.S. FDA approved the combination of lenvatinib and pembrolizumab to treat adult patients with renal cell carcinoma, the...
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with...
The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a...
Results from two clinical trials highlight the benefits of the molecularly targeted therapeutics ceritinib and osimertinib There has been...
Enfortumab vedotin-ejfv plus pembrolizumab was approved for certain bladder cancers. The U.S. Food and Drug Administration (FDA) has approved...
The FDA approved a combination of an immunotherapy and a therapeutic that can stop tumors from growing blood vessels...
The FDA approved abemaciclib with endocrine therapy for HR-positive, HER2-negative, early-stage breast cancer at high risk of recurrence. The...
The U.S. Food and Drug Administration approval provides a new option for patients with the most common type of...
The FDA approved a molecularly targeted therapeutic for postmenopausal women with HR-positive, HER2-negative breast cancer. The U.S. Food and...
The U.S. Food and Drug Administration approval of niraparib means there are now three PARP inhibitors that can be...
Patients with lung cancer who received an immune checkpoint inhibitor before surgery had improved long-term survival rates and lower...
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent for certain patients with...
The FDA approved the cellular immunotherapy axicabtagene ciloleucel for second-line treatment of patients with large B-cell lymphoma. The U.S....
The FDA has granted full approval to an antibody-drug conjugate for certain patients with breast cancer. The U.S. Food...
The CAR T-cell therapy lisocabtagene maraleucel was approved for the second-line treatment of certain patients with large B-cell lymphoma. ...
The FDA has approved a new molecularly targeted therapeutic to treat breast cancer patients with a specific subtype of...
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients...
The FDA has expanded the use of a CD30-targeted antibody?drug conjugate to include two additional types of lymphoma. The...
Approved immunotherapeutics release different brakes on the immune system. A new combination of cancer immunotherapeutics – ipilimumab (Yervoy) and...
The study, published in an AACR journal, comes after an FDA warning regarding the potential for secondary malignancies after...
Improving the rates of cervical cancer screening and HPV vaccination could have significant benefits on this form of cancer....
Lung cancer screening linked to lower mortality in real-world data, and researchers study unusual cancer patterns after COVID-19 infection.
New interventions and therapies lead to a near doubling of survival of patients with acute lymphoblastic leukemia following relapse...